Gene therapies have extended survival in muscular dystrophy, requiring improved care transitions from pediatric to adult systems. Current systems lack adequate staffing, specialists, and communication ...

Fuchs’ dystrophy is an eye condition that causes the death of cells in the inner lining of the cornea. This may lead to the accumulation of fluid in the cornea and negatively affect vision. One of the ...

Becker muscular dystrophy (BMD) is a type of muscular dystrophy, a genetic condition that weakens and damages muscles. It can worsen with age. However, its symptoms are less severe than those of ...

The US Food and Drug Administration has given the green light for the first gene therapy that treats a rare form of muscular dystrophy to be used in most people who have the disease and a certain ...

The Becker muscular dystrophy (BMD) age of onset ranges from 5 to 60 years. However, some sources suggest symptoms usually develop in a person’s teens or early twenties. BMD is a type of recessive ...

In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a condition in the cornea that subsequently bears his name. The patients ...

A new study using neuromuscular electrical stimulation (NMES) in zebrafish found that certain activities may help strengthen muscles affected by Duchenne muscular dystrophy, a severe type of muscular ...

The Food and Drug Administration approved a second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months ago.

Please provide your email address to receive an email when new articles are posted on . RGX-202 was safe and well-tolerated in all 12 patients at two different doses with no serious adverse events.

Neuromuscular disease and elite sporting prowess occupy polar opposite ends of the spectrum of human physicality. Indianapolis Colts running back Nyheim Hines has lived experience of both having grown ...